Showing 4301-4310 of 6806 results for "".
- BTL Aesthetics Announces FDA Clearance for Thighshttps://practicaldermatology.com/news/btl-aesthetics-announces-fda-clearance-for-thighs/2458475/The FDA awarded BTL Aesthetics a new designation for it non-invasive fat reduction treatment, BTL Vanquish ME—the treatment is now FDA-cleared for the circumferential reduction of the abdomen and thighs. The clearance was secured following several rounds of clinical testing to provide ample
- Dermatologist Todd Schlesinger to Host Bellafill Discussion Fridayhttps://practicaldermatology.com/news/dermatologist-todd-schlesinger-to-host-bellafill-discussion-friday/2458484/Todd E. Schlesinger, MD, FAAD will host a program on behalf of Suneva, in which he will discuss Suneva's Bellafill® and other products. The event will be held Friday, July 29th, 2016 at 8pm at Towne Stove and Spirits, 900 Boylston Street, Boston. Those interested in atte
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Indoor Tanning Rates Among Minors in NJ Stays Same Despite 2013 Banhttps://practicaldermatology.com/news/indoor-tanning-rates-among-minors-in-nj-stays-same-despite-2013-ban/2458494/Indoor tanning rates among children under age 17 in New Jersey didn’t budge after a ban enacted in 2013, and rates increased among male high school students in the Garden State from 2012 to 2014, according to a study in the Journal
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approv
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Submental Fullnesshttps://practicaldermatology.com/news/allergan-receives-positive-opinion-through-european-decentralised-procedure-for-belkyra-deoxycholic-acid-for-submental-fullness/2458511/The Swedish Medical Products Agency (MPA) gave its thumbs up to Allergan’s BELKYRA® (deoxycholic acid). BELKYRA® is being
- Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasishttps://practicaldermatology.com/news/global-psoriasis-survey-85-of-us-respondents-faced-social-stigma-because-of-psoriasis/2458514/Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have suffered from social stigma like discrimination and humiliation because of their disease. In additi